

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**華潤醫藥集團有限公司**

**China Resources Pharmaceutical Group Limited**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 3320)**

**MAJOR TRANSACTION  
IN RELATION TO THE PROPOSED ACQUISITION OF  
A CONTROLLING STAKE IN  
BOYA BIO-PHARMACEUTICAL GROUP**

**PROGRESS UPDATE**

Reference is made to the announcements of China Resources Pharmaceutical Group Limited (the “**Company**”) dated 28 September 2020, 23 October 2020, 14 December 2020, 10 February 2021 and 7 May 2021 (the “**Announcements**”) and the circular of the Company dated 24 December 2020 (the “**Circular**”) in relation to the proposed acquisition of a controlling stake in Boya Bio-pharmaceutical Group Co. Ltd. (the “**Proposed Transactions**”). Unless otherwise defined herein or the context requires, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcements and the Circular.

**PROGRESS OF THE PROPOSED TRANSACTIONS**

The Board is pleased to announce that CR Pharmaceutical Holdings has received the approval letter dated 6 July 2021 issued by the State-owned Assets Supervision and Administration Commission of the State Council (the “**SASAC**”) (Guo Zi Chan Quan [2021] No. 301), pursuant to which, the SASAC, among other things, granted an approval in-principle for the transfer of 69,331,978 non-restricted tradable shares of the Target Company and entrustment of voting rights to CR Pharmaceutical Holdings contemplated and the subscription of shares of the Target Company as contemplated under the Proposed Transactions.

As disclosed in the Announcements and the Circular, the Proposed Transactions contemplated under the Transaction Documents and the Supplemental Transaction Documents are subject to the fulfilment of certain conditions precedents stated thereunder. As of the date of this announcement, (i) the proposed transfer of shares of the Target Company contemplated under the Proposed Transactions remained subject to the application for registration of share transfer with the Shenzhen Branch of China Securities Depository and Clearing Corporation upon the compliance confirmation of the Shenzhen Stock Exchange, and the entrustment of voting right shall take effect upon completion of such transfer of shares of the Target Company; and (ii) the subscription of shares of the Target Company contemplated under the Proposed Transactions remained subject to review by the Shenzhen Stock Exchange and registration of the CSRC.

The Company will make further announcement(s) with respect to the progress of the Proposed Transactions as and when necessary and appropriate.

**Shareholders and potential investors should note that the Proposed Transactions contemplated under the Transaction Documents and the Supplemental Transaction Documents are subject to the fulfilment of the conditions precedent stated thereunder and may or may not proceed. Accordingly, Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.**

By Order of the Board  
**China Resources Pharmaceutical Group Limited**  
**Wang Chuncheng**  
*Chairman*

Shenzhen, 6 July 2021

*As at the date of this announcement, the Board comprises Mr. Wang Chuncheng as chairman and non-executive Director, Mr. Han Yuewei, Mr. Li Xiangming and Mdm. Weng Jingwen as executive Directors, Mr. Yu Zhongliang, Mdm. Guo Wei, Mr. Hou Bo and Mr. Qing Mei Ping Cuo as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.*